These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 28196920)
1. Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease. Lin N; Huang J; Violante S; Orsini JJ; Caggana M; Hughes EE; Stevens C; DiAntonio L; Chieh Liao H; Hong X; Ghomashchi F; Babu Kumar A; Zhou H; Kornreich R; Wasserstein M; Gelb MH; Yu C Clin Chem; 2017 Apr; 63(4):842-851. PubMed ID: 28196920 [TBL] [Abstract][Full Text] [Related]
2. Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease. Liao HC; Chan MJ; Yang CF; Chiang CC; Niu DM; Huang CK; Gelb MH Clin Chem; 2017 Jul; 63(7):1271-1277. PubMed ID: 28450385 [TBL] [Abstract][Full Text] [Related]
3. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Dajnoki A; Mühl A; Fekete G; Keutzer J; Orsini J; Dejesus V; Zhang XK; Bodamer OA Clin Chem; 2008 Oct; 54(10):1624-9. PubMed ID: 18703766 [TBL] [Abstract][Full Text] [Related]
4. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590 [TBL] [Abstract][Full Text] [Related]
5. Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651 [TBL] [Abstract][Full Text] [Related]
6. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis. Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815 [TBL] [Abstract][Full Text] [Related]
7. Current status of newborn screening for Pompe disease in Japan. Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579 [TBL] [Abstract][Full Text] [Related]
8. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ]. Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692 [No Abstract] [Full Text] [Related]
9. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Labrousse P; Chien YH; Pomponio RJ; Keutzer J; Lee NC; Akmaev VR; Scholl T; Hwu WL Mol Genet Metab; 2010 Apr; 99(4):379-83. PubMed ID: 20080426 [TBL] [Abstract][Full Text] [Related]
10. Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population. Lee JH; Shin JH; Park HJ; Kim SZ; Jeon YM; Kim HK; Kim DS; Choi YC Neuromuscul Disord; 2017 Jun; 27(6):550-556. PubMed ID: 28433475 [TBL] [Abstract][Full Text] [Related]
12. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant. Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071 [TBL] [Abstract][Full Text] [Related]
13. Gene Therapy for Pompe Disease: The Time is now. Colella P; Mingozzi F Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581 [TBL] [Abstract][Full Text] [Related]
14. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease. Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108 [TBL] [Abstract][Full Text] [Related]
15. [Establishment and clinical application of dried blood spots and mixed leukocytes for determination of acid alpha-glucosidase activity]. Qiu WJ; Wang X; Wang Y; Ye J; Han LS; Zhang HW; Gu XF Zhonghua Er Ke Za Zhi; 2010 Jan; 48(1):55-9. PubMed ID: 20441705 [TBL] [Abstract][Full Text] [Related]
16. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. Confalonieri M; Vitacca M; Scala R; Polverino M; Sabato E; Crescimanno G; Ceriana P; Antonaglia C; Siciliano G; Ring N; Zacchigna S; Salton F; Vianello A; Orphanet J Rare Dis; 2019 Mar; 14(1):62. PubMed ID: 30832705 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease. Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH; Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307 [TBL] [Abstract][Full Text] [Related]
19. Pompe disease: early diagnosis and early treatment make a difference. Chien YH; Hwu WL; Lee NC Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029 [TBL] [Abstract][Full Text] [Related]